Eli Lilly's Foundayo: The New Contender in the Weight-Loss Pill Arena

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's new weight-loss pill, Foundayo, marking a new chapter in the competition against Novo Nordisk. Designed as a once-daily oral medication, Foundayo targets the GLP-1 hormone, helping trial patients shed 12% to 15% of their body weight.

Eli Lilly announced that Foundayo will be available through LillyDirect starting April 6, at a competitive price of $149 per month for the lowest self-pay dose. CEO David Ricks confirmed the company has submitted applications for approval in more than 40 countries, expecting early approvals in several major markets like the Gulf states.

Lilly's entry into this field follows Novo Nordisk's success with GLP-1 injectables and the launch of its oral Wegovy. Foundayo distinguishes itself by eliminating food intake restrictions, which could impact patient uptake. Despite a boxed warning for thyroid C-cell tumors, analysts predict oral weight-loss pills could claim around 20% of the market by 2030.